Manila Times Business
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) CLN-978 data from the first RA multi-dose regimen cohort demonstrated robust efficacy, including clinical remission in a poly-refractory patient, with a favorable safety profile Initial velinotamig (BCMA TCE) data show promising clinical activity, including complete renal responses in lupus nephritis, supporting potential in plasma
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
The ChariTree Foundation Calls for More Outdoor Learning Opportunities for Children in the Age of AI
Just now
Budweiser China Co-Hosts Global Night-Time Economy Dialogue in Shanghai, Highlighting Multinational Companies’ Role in Urban Consumption Growth
Just now
Completion of the Sale of the Share of Saare Kala Tootmine OÜ
Just now
Shufti Ranked as a Leader in G2’s Summer 2026 Identity Verification Grid® Report
Just now